Most actionable first. Assess the next decision, not the size of the database.
2 matching trial–asset observations. These are not unique or cleared acquisitions. 0 have all four gates supported in this view; entered assessments still require review.
How “most actionable” works
Explicit ordinal order: all four gates PASS → concerns needing review → unresolved leads → fatal failures. Names and IDs break ties. UNKNOWN never counts as a pass. This is not an efficacy score or valuation. Private assumptions affect only your own results.
Advanced Neuroendocrine Carcinomas of The Digestive System, Advanced Neuroendocrine Carcinomas Unknown Primary Origin
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT AMGEN, due to a change in priorities within the Tarlatamab programme, has decided to withdraw its support for the study, which means the clinical trial will be...
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
AMGEN, due to a change in priorities within the Tarlatamab programme, has decided to withdraw its support for the study, which means the clinical trial will be terminated early.
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Advanced Neuroendocrine Carcinomas of The Digestive System, Advanced Neuroendocrine Carcinomas Unknown Primary Origin
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT AMGEN, due to a change in priorities within the Tarlatamab programme, has decided to withdraw its support for the study, which means the clinical trial will be...
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
AMGEN, due to a change in priorities within the Tarlatamab programme, has decided to withdraw its support for the study, which means the clinical trial will be terminated early.
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established